{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:47:43Z","timestamp":1788306463866,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fosfomycin has become a therapeutic option in urinary tract infections. Our objective was to evaluate the in vitro activity of fosfomycin against\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    isolated from urine samples in 2013, 2018 and 2021. We also determined a putative association between fosfomycin resistance and extended-spectrum \u03b2-lactamases (ESBL) production. Fosfomycin activity was evaluated against 7367, 8128 and 5072\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    urinary isolates in 2013, 2018 and 2021, respectively. We compare the prevalence of fosfomycin-resistant strains among the ESBL- and non-ESBL-producing isolates. MICs of fosfomycin, cefotaxime, and cefotaxime-clavulanate were determined by a microdilution method. 302 ESBL-producers were selected to determine MICs of fosfomycin by agar dilution and genes encoding ESBLs were detected by PCR. Among the total of ESBL-producing strains, 14.3%, 20.8% and 20% were resistant to fosfomycin in 2013, 2018 and 2021, respectively, whereas fosfomycin resistance in non-ESBL producers was 3.5%, 4.05% and 5.53% for each year (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009\u2264\u20090.001). In the 302 selected ESBL-producing isolates, CTX-M was the main ESBL (228 isolates), being 50.7% CTX-M-15. Resistance to fosfomycin among these ESBL-producing strains was associated (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.049) with isolates that produced the CTX-M type. Our data show that fosfomycin resistance is increasing in\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    urinary isolates and it is related to ESBL-production. A follow-up of fosfomycin resistance is required.\n                  <\/jats:p>","DOI":"10.1007\/s00430-022-00749-2","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T04:02:47Z","timestamp":1662177767000},"page":"269-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum \u03b2-lactamase-production in urinary isolates of Escherichia coli"],"prefix":"10.1007","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5604-5967","authenticated-orcid":false,"given":"Esther","family":"R\u00edos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"del Carmen L\u00f3pez Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Culebras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iciar","family":"Rodr\u00edguez-Avial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rodr\u00edguez-Avial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"issue":"6\u20137","key":"749_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ijmm.2013.02.008","volume":"303","author":"MM D'Andrea","year":"2013","unstructured":"D\u2019Andrea MM, Arena F, Pallecchi L, Rossolini GM (2013) CTX-M-type beta-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol 303(6\u20137):305\u2013317","journal-title":"Int J Med Microbiol"},{"issue":"10","key":"749_CR2","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1128\/AAC.00688-09","volume":"53","author":"N Woodford","year":"2009","unstructured":"Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM (2009) Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. Antimicrob Agents Chemother 53(10):4472\u20134482","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"749_CR3","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52(5):e103\u2013e120","journal-title":"Clin Infect Dis"},{"issue":"3","key":"749_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.10.019","volume":"35","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G (2010) Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 35(3):240\u2013243","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"749_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/QCO.0b013e3283398dc1","volume":"23","author":"J Oteo","year":"2010","unstructured":"Oteo J, Perez-Vazquez M, Campos J (2010) Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 23(4):320\u2013326","journal-title":"Curr Opin Infect Dis"},{"key":"749_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/antibiotics2020217","volume":"2","author":"A Casta\u00f1eda-Garc\u00eda","year":"2013","unstructured":"Casta\u00f1eda-Garc\u00eda A, Bl\u00e1zquez J, Rodr\u00edguez-Rojas A (2013) Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics 2:217\u2013236","journal-title":"Antibiotics"},{"key":"749_CR7","unstructured":"CLSI. (2009) Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. 29(3): CLSI document M100-S19. CLSI, Wayne, PA.3."},{"key":"749_CR8","unstructured":"Testing EUCAST. (2013) Break-point tables for interpretation of MICs and zone diameters. Version 3.1. European Committee on Antimicrobial Susceptibility Testing. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Breakpoint_table_v_3.1.pdf"},{"key":"749_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1128\/AAC.46.2.500-510.2002","volume":"46","author":"TM Coque","year":"2002","unstructured":"Coque TM, Oliver A, Perez-Diaz JC, Baquero F, Canton R (2002) Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother 46:500\u2013510","journal-title":"Antimicrob Agents Chemother"},{"key":"749_CR10","doi-asserted-by":"publisher","first-page":"106296","DOI":"10.1016\/j.mimet.2021.106296","volume":"188","author":"N Kansak","year":"2021","unstructured":"Kansak N, Ar\u0131c\u0131 N, Adaleti R, Nakipoglu Y, Aksaray S (2021) Rapid detection of fosfomycin resistance in Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections. J Microbiol Methods 188:106296","journal-title":"J Microbiol Methods"},{"issue":"4","key":"749_CR11","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/jac\/dkp288","volume":"64","author":"J Oteo","year":"2009","unstructured":"Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Mart\u00ednez-Ruiz R et al (2009) CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 64(4):712\u2013717","journal-title":"J Antimicrob Chemother"},{"key":"749_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jgar.2020.01.023","volume":"21","author":"C Loras","year":"2020","unstructured":"Loras C, Constan\u00e7a Mendes A, Peixe L, Novais \u00c2, Al\u00f3s JI (2020) Escherichia coli resistant to fosfomycin from urinary tract infections: detection of the fosA3 gene in Spain. J Glob Antimicrob Resist 21:414\u2013416","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"749_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","volume":"10","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE (2010) Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2- lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 10(1):43\u201350","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"749_CR14","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/jac\/dkq346","volume":"65","author":"J Oteo","year":"2010","unstructured":"Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernandez S et al (2010) Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 65(11):2459\u20132463","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"749_CR15","first-page":"43","volume":"26","author":"C Rodriguez-Avial","year":"2013","unstructured":"Rodriguez-Avial C, Rodriguez-Avial I, Hernandez E, Picazo JJ (2013) Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005\u20132009-2011). Rev Esp Quimioter 26(1):43\u201346","journal-title":"Rev Esp Quimioter"},{"issue":"4","key":"749_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ijantimicag.2009.11.011","volume":"35","author":"S Takahata","year":"2010","unstructured":"Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K, Terada S et al (2010) Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 35(4):333\u2013337","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"749_CR17","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1128\/AAC.01834-09","volume":"54","author":"J Wachino","year":"2010","unstructured":"Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y (2010) Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother 54(7):3061\u20133064","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"749_CR18","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1128\/AAC.05104-11","volume":"56","author":"J Hou","year":"2012","unstructured":"Hou J, Huang X, Deng Y, He L, Yang T, Zeng Z et al (2012) Dissemination of the fosfomycin resistance gene fosA3 with CTX-M beta-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China. Antimicrob Agents Chemother 56(4):2135\u20132138","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-022-00749-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00430-022-00749-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-022-00749-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T12:03:48Z","timestamp":1667131428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00430-022-00749-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":18,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s00430-022-00749-2","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}